IMVTImmunovant, Inc.

HealthcareUSD
$43.90

The financials

Immunovant, Inc. by the numbers

Immunovant, Inc. income statement, Q1 2027 against the same quarter a year earlier
Income statementQ1 2027Q1 2026Change
Net income−$153M−$121Mn/a
Diluted EPS−$0.75−$0.71n/a

Biotechnology

Ranks #36 of 145 by Smart Score

Compare peers
PTGX+0.39%
Protagonist Therapeutics, Inc.
PCVX-0.35%
Vaxcyte, Inc.
SYRE+2.8%
Spyre Therapeutics, Inc.
IBRX-0.13%
ImmunityBio, Inc.
TGTX+0.06%
TG Therapeutics, Inc.
RYTM+0.66%
Rhythm Pharmaceuticals, Inc.